Benjamin Besse, MD

Articles

Future Research Directions in ALK+ and ROS1+ NSCLC

October 29th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Lorlatinib in ROS1+ Advanced NSCLC After Crizotinib and Chemotherapy

October 29th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.

The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC

October 29th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLC

October 28th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Preclinical CNS Data for Zidesamtinib and Other ROS1 Inhibitors

October 28th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.

Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors

October 28th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.

Data for NVL-655 in Advanced ALK+ NSCLC and Solid Tumors from the ALKOVE-1 Trial

October 25th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.

Testing for ALK Fusions and ROS1 Rearrangements in NSCLC

October 25th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

October 4th 2024

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Phase I/II ARROS-1 Study of Zidesamtinib (NVL-520) in ROS1 Fusion-positive Solid Tumours

September 30th 2024

The ARROS-1 Phase 1/2 study investigates the safety, tolerability, and efficacy of zidesamtinib (NVL-520), a ROS1-selective, brain-penetrant tyrosine kinase inhibitor, in heavily pre-treated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, showing promising durable responses in both systemic and intracranial disease.

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

September 11th 2024

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

April 10th 2021

Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.

Dr. Besse on Combination of Necitumumab and Abemaciclib in NSCLC

May 17th 2018

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of necitumumab (Portrazza) and abemaciclib (Verzenio) in patients with stage IV non–small cell lung cancer.

Dr. Besse Discusses Challenges Facing Stage IV NSCLC

April 13th 2018

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non

Dr. Besse on the Combination of Treatments for NSCLC

September 20th 2017

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non